Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific cd8+ T-cell immunity

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1084-1094

  Brown, Matthew D ^a   Van der Most, Robbert ^b   Vivian, Justin B ^c   Lake, Richard A ^c   Larma, Irma ^a   Robinson, Bruce W S ^c   Currie, Andrew J ^c,d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d MURDOCH UNIVERSITY   (Australia)

Author keywords

CD8+ T cell; Cross presentation; Cross priming; Immunotherapy; Surgery

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNE DEFICIENCY; IMMUNOLOGICAL MEMORY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MALIGNANT MESOTHELIOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SURGICAL APPROACH; SUTURING METHOD; TUMOR IMMUNITY; WILD TYPE; WOUND CLOSURE;

EID: 84880088056     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20924     Document Type: Article

References (39)

1. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460-7; PMID:7923001; http://dx.doi. org/10.1002/1097-0142(19941101)74:9<2460::AIDCNCR2820740912> 3.0.CO;2-N.
2. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21:211-7; PMID:9610913; http:// dx.doi.org/10.1097/00002371-199805000-00007.
3. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 2006; 52:189-97; PMID:16563560; http://dx.doi.org/10.1016/j.lungcan.2006.01.007.
4. Curti BD. Renal cell carcinoma. JAMA 2004; 292:97-100; PMID:15238597; http://dx.doi.org/10.1001/ jama.292.1.97.
5. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27:187-93; PMID:10768597.
6. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin- 2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521-9; PMID:10561318.
7. Mukherjee S, Nelson D, Loh S, van Bruggen I, Palmer LJ, Leong C, et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 2001; 8:580-8; PMID:11571536; http://dx.doi.org/10.1038/ sj.cgt.7700347.
8. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65:7580-4; PMID:16140921.
9. Repmann R, Goldschmidt AJ, Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year followup analysis. Anticancer Res 2003; 23(2A):969-74; PMID:12820332.
10. Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 1997; 17(4B):2879-82; PMID:9329553.
11. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-6; PMID:14767273; http://dx.doi.org/10.1097/01.ju.0000110610.61545. ae.
12. Bromwich E, Hendry D, Aitchison M. Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer. BJU Int 2002; 89:523-5; PMID:11942956; http://dx.doi.org/10.1046/j.1464-410X.2002.02631.x.
13. Flanigan R, Salmon M, Blumenstein B, Bearman S, Roy V, McGrath P, et al. Nephrectomy followed by interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345:1655-9; PMID:11759643; http://dx.doi.org/10.1056/NEJMoa003013.
14. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997; 158:1691-5; PMID:9334580; http://dx.doi. org/10.1016/S0022-5347(01)64097-7.
15. Walther M, Yang J, Pass H, Linehan W, Rosenberg S. Cytoreductive surgery before high dose Il-2 based therapy in patients with metastatic renal cancer. J Urol 1997; 158:1675-8; PMID:9334576; http://dx.doi. org/10.1016/S0022-5347(01)64091-6.
16. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9:3105-14; PMID:12912962.
17. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003; 17(Suppl 1):S27-36; PMID:12615183; http://dx.doi.org/10.1016/S0889-1591(02)00063-6.
18. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66:5527-36; PMID:16740684; http://dx.doi.org/10.1158/0008-5472.CAN-05-4128.
19. Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 1999; 49:101-16, 65.
20. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174:636-45; PMID:15634881.
21. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6:1755-66; PMID:10815894.
22. Benigni F, Zimmermann VS, Hugues S, Caserta S, Basso V, Rivino L, et al. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J Immunol 2005; 175:739-48; PMID:16002669.
23. Betts G, Godkin A, Gallimore A. Reply: Forkhead box P3-positive regulatory T cells in immune surveillance and cancer. Br J Cancer 2007; 97:1017-8.
24. Wichmann MW, Lau-Werner U, Müller C, Hornung HM, Stieber P, Schildberg FW; Colorectal Cancer Study Group. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res 2000; 20(6D):4953-5; PMID:11326645.
25. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141:873-9; PMID:2467013.
26. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208; PMID:16551247; http://dx.doi.org/10.1146/annurev. immunol.24.021605.090733.
27. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumorspecific CD8 T cells. J Immunol 2003; 170:4905-13; PMID:12734333.
28. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BWS. Cutting edge: tumorspecific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004; 173:5923-8; PMID:15528325.
29. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAILdependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009; 4:e6982; PMID:19746156; http://dx.doi.org/10.1371/ journal.pone.0006982.
30. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999; 162:5838-45; PMID:10229818.
31. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171:131-7; PMID:8176234; http://dx.doi. org/10.1016/0022-1759(94)90236-4.
32. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999; 59:1071-9; PMID:10070965.
33. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024-9; PMID:15173017; http://dx.doi.org/10.1158/0008-5472.CAN-03-3949.
34. McDonnell AM, Robinson BW, Currie AJ. Tumor antigen cross-presentation and the dendritic cell: where it all begins. Clin Dev Immunol 2010; 2010:539519; PMID:20976125; http://dx.doi. org/10.1155/2010/539519.
35. Kilinc MO, Rowswell-Turner RB, Gu T, Virtuoso LP, Egilmez NK. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol 2009; 183:7656-60; PMID:19923444.
36. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305; PMID:18060041; http://dx.doi. org/10.1172/JCI32103.
37. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7; PMID:16382236; http://dx.doi. org/10.1038/nature04444.
38. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 1990; 133:87-97; PMID:2212694; http://dx.doi. org/10.1016/0022-1759(90)90322-M.
39. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998; 161:5338-46; PMID:9820507.